Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

fiercebiotech.com

FierceBiotech

Get the latest updates from FierceBiotech directly as they happen.

Follow now 337 followers

Latest posts

Last updated about 8 hours ago

Clinical trial flaws ‘being scaled, not solved’ by AI: report

about 8 hours ago

Clinical trial data company Phesi’s new analysis found that fewer than one...

Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up

about 8 hours ago

Chinese companies now represent 50% of global out-licensing deals, with U.S. companies...

Incyte inks deal with Edison Scientific to train AI through drug discovery

about 8 hours ago

Incyte and Edison Scientific have signed a collaboration to employ Edison’s AI...

Merck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial

about 9 hours ago

Exelixis has secured supplies of subcutaneous Keytruda from Merck & Co. for...

Lauxera Capital Partners raises a hefty €520M for health, medtech companies

about 11 hours ago

Lauxera Capital Partners has nearly doubled the size of its first funding...

Herantis taps Indivi for digital biomarker tech in Parkinson’s disease trial

about 11 hours ago

Finnish biotech Herantis Pharma is teaming up with Swiss medtech Indivi to...

Relay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder

about 13 hours ago

Relay Therapeutics’ R&D chief remains convinced the biotech’s PI3Kα inhibitor will carve...

Sanofi and Wave post AATD updates in race to end genetic disease’s 40-year new treatment drought

1 day ago

Sanofi and Wave Life Sciences are using their time at the annual...

Vincetage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators

1 day ago

Vincentage Pharma’s oral GLP-1 agonist has been tied to mean weight loss...

BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal

1 day ago

BioMarin’s $270 million bet on Inozyme’s enzyme replacement therapy looks in trouble...

After rare disease flop, cash-strapped Quince finds salvation in reverse merger

1 day ago

After launching a hunt for strategic alternatives in January following a phase...

Nominations now open for Fierce Biotech's 2026 Fierce 15

1 day ago

It's time to kick off our annual hunt for the latest crop...